Medications like Ozempic and Wegovy, known for treating diabetes and aiding in weight loss, may have an unexpected health benefit: reducing cancer risk. Researchers are investigating whether these drugs, which contain glucagon-like peptide-1 (GLP-1), are linked to lower cancer diagnoses and recurrence rates.
Preliminary Findings
While current research suggests an association between GLP-1 use and certain cancer outcomes, it does not prove that the medications directly prevent cancer or treat existing disease. Dr. Loren Rourke, a Texas-based breast cancer surgeon, notes that patients should not view the findings as proof that the medications can prevent cancer.
Rourke points to findings presented at the 2026 American Society of Clinical Oncology annual meeting, where researchers reported a connection between GLP-1 medication use and lower breast cancer recurrence rates. However, she emphasizes that more research is needed to determine whether GLP-1 medications themselves reduce cancer risk or if the benefits are primarily linked to related changes such as weight loss and improved metabolic health.
Potential Mechanisms
Researchers believe that one possible explanation involves the way GLP-1 medications affect weight, inflammation, and hormones. The drugs help regulate blood sugar and appetite, often leading to significant weight loss. Excess body weight can increase the risk of several cancers, including some forms of breast cancer. Reducing body weight may provide additional health benefits, as lower body mass index (BMI) has been associated with improved outcomes for some cancer patients.
GLP-1 medications may also influence chronic inflammation, a biological process linked to cancer development. Excess body fat can contribute to higher levels of inflammation and increased estrogen production, factors that may play a role in certain cancers.
The potential impact could extend beyond breast cancer, but more research is needed before doctors can make treatment recommendations based on cancer prevention. Randomized controlled trials are necessary to determine the effects of GLP-1 medications on cancer risk.
Original reporting: WOWO News/Talk (Fort Wayne) — read the source article.
